Literature DB >> 19933861

Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

Nicolas Cuburu1, Mi-Na Kweon, Catherine Hervouet, Hye-Ran Cha, Yuk-Ying S Pang, Jan Holmgren, Konrad Stadler, John T Schiller, Fabienne Anjuère, Cecil Czerkinsky.   

Abstract

We have recently reported that the sublingual (s.l.) mucosa is an efficient site for inducing systemic and mucosal immune responses. In this study, the potential of s.l. immunization to induce remote Ab responses and CD8(+) cytotoxic responses in the female genital tract was examined in mice by using a nonreplicating Ag, OVA, and cholera toxin (CT) as an adjuvant. Sublingual administration of OVA and CT induced Ag-specific IgA and IgG Abs in blood and in cervicovaginal secretions. These responses were associated with large numbers of IgA Ab-secreting cells (ASCs) in the genital mucosa. Genital ASC responses were similar in magnitude and isotype distribution after s.l., intranasal, or vaginal immunization and were superior to those seen after intragastric immunization. Genital, but not blood or spleen, IgA ASC responses were inhibited by treatment with anti-CCL28 Abs, suggesting that the chemokine CCL28 plays a major role in the migration of IgA ASC progenitors to the reproductive tract mucosa. Furthermore, s.l. immunization with OVA induced OVA-specific effector CD8(+) cytolytic T cells in the genital mucosa, and these responses required coadministration of the CT adjuvant. Furthermore, s.l. administration of human papillomavirus virus-like particles with or without the CT adjuvant conferred protection against genital challenge with human papillomavirus pseudovirions. Taken together, these findings underscore the potential of s.l. immunization as an efficient vaccination strategy for inducing genital immune responses and should impact on the development of vaccines against sexually transmitted diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933861      PMCID: PMC7370923          DOI: 10.4049/jimmunol.0803740

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

Authors:  F W van Ginkel; R J Jackson; Y Yuki; J R McGhee
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

Review 2.  Plasma-cell homing.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

3.  In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin.

Authors:  Fabienne Anjuère; Carmelo Luci; Michael Lebens; Déborah Rousseau; Catherine Hervouet; Geneviève Milon; Jan Holmgren; Carlos Ardavin; Cecil Czerkinsky
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

4.  Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

Authors:  A Rudin; E L Johansson; C Bergquist; J Holmgren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

5.  Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.

Authors:  E L Johansson; C Rask; M Fredriksson; K Eriksson; C Czerkinsky; J Holmgren
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

6.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 7.  Vaginal immunity in the HSV-2 mouse model.

Authors:  Margaret B Parr; Earl L Parr
Journal:  Int Rev Immunol       Date:  2003 Jan-Feb       Impact factor: 5.311

8.  Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.

Authors:  D Nardelli-Haefliger; R Roden; C Balmelli; A Potts; J Schiller; P De Grandi
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.

Authors:  Igor M Belyakov; Dmitry Isakov; Qing Zhu; Amiran Dzutsev; Jay A Berzofsky
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

10.  Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2.

Authors:  Xinyan Zhao; Eszter Deak; Kelly Soderberg; Melissa Linehan; David Spezzano; Jia Zhu; David M Knipe; Akiko Iwasaki
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  46 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

2.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

3.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

4.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

Review 5.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.

Authors:  Prosper N Boyaka
Journal:  J Immunol       Date:  2017-07-01       Impact factor: 5.422

6.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

7.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

8.  Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells.

Authors:  C Hervouet; C Luci; S Bekri; T Juhel; F Bihl; V M Braud; C Czerkinsky; F Anjuère
Journal:  Mucosal Immunol       Date:  2013-06-26       Impact factor: 7.313

9.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

10.  Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice.

Authors:  Marianne Quiding-Järbrink; Sukanya Raghavan; Malin Sundquist
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.